- Palella, F.J., Jr., et al., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med, 1998. 338(13): p. 853-60.
- Greenwald, J.L., et al., A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep, 2006. 8(2): p. 125-31.
- King, K.M., et al., Co-occurrence of Sexual Risk Behaviors and Substance Use Across Emerging Adulthood: Evidence for State- and Trait-level Associations. Addiction, 2012.
- The NSDUH Report: HIV/AIDS and Substance Use, 2010, Substance Abuse and Mental Health Services Administration: Rockville, MD.
- Marcondes, M.C., et al., Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol, 2010. 177(1): p. 355-61.
- Langford, D., et al., Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr, 2003. 34(5): p. 467-74.
- Rippeth, J.D., et al., Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc, 2004. 10(1): p. 1-14.
- Cohen, S.M., et al., Vital Signs: HIV Prevention Through Care and Treatment - United States, in Morbidity and Mortality Weekly Report 2011, Centers for Disease Control and Prevention. p. 1618-1623.
- Degenhardt, L., et al., Meth/ amphetamine use and associated HIV: Implications for global policy and public health. Int J Drug Policy, 2010. 21(5): p. 347-58.
- Phair, J. and F. Palella, Renal disease in HIV-infected individuals. Curr Opin HIV AIDS, 2011. 6(4): p. 285-9.
- Mallon, P.W., HIV and bone mineral density. Curr Opin Infect Dis, 2010. 23(1): p. 1-8.
- Falade-Nwulia, O. and C.L. Thio, Liver disease, HIV and aging. Sex Health, 2011. 8(4): p. 512-20.
- Dukers, N.H., et al., Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS, 2001. 15(3): p. 369-78.
- Vanable, P.A., et al., Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychol, 2000. 19(2): p. 134-45.
- Boily, M.C., et al., Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models. Sex Transm Dis, 2004. 31(2): p. 100-13.
- Tun, W., et al., Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug users. AIDS, 2003. 17(13): p. 1953-62.
- Rahmanian, S., et al., Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc, 2011. 8(3): p. 313-9.
- Wejnert, C., et al., HIV Infection and HIVAssociated Behaviors Among Injecting Drug Users - 20 Cities, United States, 2009, in Morbidity and Mortality Weekly Report 2012, Centers for Disease Control and Prevention. p. 133-138.
- Stone, V.E., HIV/AIDS in Women and Racial/ Ethnic Minorities in the U.S. Curr Infect Dis Rep, 2012. 14(1): p. 53-60.
- Intersecting Risks:HIV Infection Among Heterosexual Women and Men in Massachusetts, 2010, Bureau of Infectious Disease, Office of HIV/AIDS.
- Machtinger, E.L., et al., Psychological Trauma and PTSD in HIV-Positive Women: A Meta-Analysis. AIDS Behav, 2012.
- Armstrong, G.L., et al., The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med, 2006. 144(10): p. 705-14.
- Ghany, M.G., et al., An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 2011. 54(4): p. 1433-44.
- Hallfors, D.D., et al., Sexual and drug behavior patterns and HIV and STD racial disparities: the need for new directions. Am J Public Health, 2007. 97(1): p. 125-32.
- Currier, J., et al., Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med, 2010. 153(6): p. 349-57.
- Althoff, K.N., et al., CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther, 2010. 7: p. 45.
- Smith, G., HIV Over Fifty: Exploring the New Threat, in Special Committee on Aging, U.S. Senate 2005, U.S. Government Printing Office: Washington, D.C. p. 1.
- Doyle, K., et al., Aging, Prospective Memory, and Health-Related Quality of Life in HIV Infection. AIDS Behav, 2012.
- Maruschak, L.M., Bureau of Justice Statistics: HIV in Prisons, 2007-2008, 2010, U.S. Department of Justice.
- Spaulding, A.C., et al., HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One, 2009. 4(11): p. e7558.
- Mumola, C.J. and J.C. Karber, Special Report: Drug Use and Dependence, State and Federal Prisoners, 2004, 2007, U.S. Department of Justice.
- Beckwith, C.G., et al., Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr, 2010. 55 Suppl 1: p. S49-55.
- Metzger, D.S., H. Navaline, and G.E. Woody, Drug abuse treatment as AIDS prevention. Public Health Rep, 1998. 113 Suppl 1: p. 97-106.
- Schroeder, J.R., et al., Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav, 2006. 31(5): p. 868-79.
- Westergaard, R.P., et al., Provider and cliniclevel correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc, 2012. 15: p. 10.
- Wood, E., et al., Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA, 2008. 300(5): p. 550-4.
- Roux, P., et al., The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction, 2008. 103(11): p. 1828-36.
- Korthuis, P.T., et al., Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr, 2011. 56 Suppl 1: p. S83-90.
- McCance-Katz, E.F., Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis, 2005. 41 Suppl 1: p. S89-95.
- McCance-Katz, E.F. and T.W. Mandell, Drug interactions of clinical importance with methadone and buprenorphine. Am J Addict, 2010. 19(1): p. 2-3.
- Carrieri, M.P., et al., Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend, 2000. 60(1): p. 51-4.
- Sanders, G.D., et al., Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med, 2005. 352(6): p. 570-85.
- Cohen, M.S., et al., Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011. 365(6): p. 493-505.
- Montaner, J.S., et al., Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet, 2010. 376(9740): p. 532-9.
- Kirk, G., et al., Decline in Community Viral Load Strongly Associated with Declining HIV Incidence among IDU, in 18th Conference on Retroviruses and Opportunistic Infections 2011: Boston, MA.
Cite this article
NIDA. (2012, July 1). HIV/AIDS. Retrieved from https://www.drugabuse.gov/publications/research-reports/hivaids
This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.